Myda Advisors LLC Bio Atla, Inc. Transaction History

Myda Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$1.37 - $3.92 $109,600 - $313,600	-80,000 Reduced 44.44%	100,000 $137,000
Q1 2024 May 14, 2024	SELL	$1.88 - $3.46 $75,200 - $138,400	-40,000 Reduced 18.18%	180,000 $619,000
Q4 2023 Feb 13, 2024	BUY	$1.27 - $3.18 $228,600 - $572,400	180,000 Added 450.0%	220,000 $541,000
Q3 2023 Nov 14, 2023	SELL	$1.7 - $3.07 $34,000 - $61,400	-20,000 Reduced 33.33%	40,000 $68,000
Q2 2023 Aug 11, 2023	BUY	$2.83 - $3.87 $14,150 - $19,350	5,000 Added 9.09%	60,000 $180,000
Q1 2023 May 12, 2023	BUY	$2.3 - $8.25 $126,499 - $453,750	55,000 New	55,000 $147,000
Q2 2022 Aug 12, 2022	BUY	$2.13 - $5.38 $29,820 - $75,320	14,000 Added 23.33%	74,000 $211,000
Q1 2022 May 13, 2022	BUY	$4.38 - $18.78 $262,800 - $1.13 Million	60,000 New	60,000 $300,000

17.3M

500

33.5K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $62.4M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Myda Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Myda Advisors LLC with notifications on news.